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M  protein on the surface of group A streptococci renders the organism resistant to 
phagocytosis in the nonimmune host. Antibody directed against this surface antigen 
is opsonie for homologous-type organisms and promotes phagocytosis and killing in 
the immune host. The immune response to the M  protein antigen has been thought 
to be universally type specific, resulting in a unique population of protective antibodies 
against  each  serotype  of M  protein.  Increasingly  sensitive  immunological  assays, 
however, have pointed toward significant cross-reactivity among different serotypes. 
Cross-protection  between  M  serotypes  was  first  reported  in  1939  by  Hirst  and 
Lancefield  (1), who immunized mice with crude acid extracts of M  protein.  Later, 
Wiley and Wilson  (2)  described cross-protection between  the M  proteins of certain 
type 14 and 51 strains. Their data suggested the presence of two distinct protective M 
protein antigens in the cross-reactive strains; however, the possibility that the antigens 
resided  in  a  single  protein  molecule was  not  excluded.  Wiley and  Bruno  (3)  later 
described a  number of cross-reactions, some of which were protective, among types 
33,  41,  43,  52,  and  "Ross"  after  injection  of rabbits  with  heat-killed  organisms. 
Unidirectional,  cross-protective antibody  between  types  55  and  60  was  shown  by 
Bergner-Rabinowitz  et  al.  (4)  to  develop  in  humans  and  rabbits.  These  studies 
suggested  that  some of the  M  antigens  shared  certain  protective  (or opsonogenic) 
determinants. 
Several investigations have suggested that streptococcal M  protein is composed of 
heterogeneous  subunits,  each  of which  possesses  antigenic  type  specificity  (5-12). 
Although  whether or not  the multiple determinants  were identical  or antigenically 
distinct was not clearly established, the observations that certain antisera precipitated 
M  protein  but  were not  opsonic  (10,  11),  whereas others were opsonic but  did  not 
precipitate M  protein (11,  13), suggested the existence of distinct antigenic sites. More 
recently,  Fischetti  (14),  with  a  sensitive radioimmunoassay, obtained  data  showing 
heterogeneity of the immune response to a single serotype-6 M  protein. He presented 
evidence to suggest  that  some of the heterogeneous determinants  were shared with 
other  M  serotypes and,  furthermore,  demonstrated  a  correlation  of cross-reactivity 
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among different serotypes of M  protein with the presence of several common tryptic 
peptides,  thus suggesting  certain  structural  similarities  among  the types  examined 
(15). 
Our  investigation  was  undertaken  to  study  the  antigenic  diversity  of  a  single 
polypeptide of M  protein known to be composed of repeating primary structures (12). 
Purified pepsin extracts of types-5, -6, and -24 M  proteins (pep M5, pep M6, and pep 
M24) 1 were used as antigens in the enzyme-linked immunosorbent assay  (ELISA)  to 
analyze the immune response in humans immunized with one of these preparations, 
pep M24. We present evidence to show that immunization with pep M24 can lead to 
the production of IgG class antibodies that cross-react with pep M6 and pep M5, and 
that  a  portion  of  the  cross-reactive  antibodies  afford  cross-protection.  Moreover, 
immunoinhibition  studies with  cyanogen  bromide  peptide  fragments  derived  from 
pep  M24  indicate  (a)  that  the  M  protein  molecule  is  antigenically  heterogeneous, 
possessing  several  distinct  as  well  as  identical  type-specific  antigenic  determinants, 
and (b) that pep M24 contains an inaccessible cross-reactive determinant that becomes 
exposed only after fragmentation of the intact molecule. 
Materials and Methods 
M  Protein.  M  proteins  from  limited  peptic  digests of intact  types-5,  -6,  and  -24 group  A 
streptococci  were  obtained  in  pure  form  as  judged  by  sodium  dodecyl  sulfate  (SDS)-gel 
electrophoresis and amino terminal sequence analysis as described elsewhere in detail (16-18). 
The purified peptic extracts (pep M5, pep M6, and pep M24) were assayed for the presence of 
type-specific precipitating  and  opsonic  antigens  by capillary  precipitation  and  opsonization 
inhibition tests, r~spectively (16,  19). Cyanogen bromide (CNBr)  peptides were prepared from 
pep M24 and purified as previously described (12,  18). 
Human Serum.  Sera used in this study were obtained from healthy volunteers who received 
immunizing  doses  of pep  M24.  The  immunization  protocols  have  been  reported  in  detail 
elsewhere (17).  Briefly, volunteers between the ages of 22 and 58  (mean age:  29) who did not 
have histories or evidence of cardiac or renal disease, rheumatic fever, or atopic allergies were 
given  intradermal  skin  tests  with  0.1-1.0  /lg of pep  M24  and  pep  M6.  Negative  skin-test 
individuals who were chosen for the vaccination studies received an alum-precipitated pep M24 
vaccine in  doses  of  100-200  /xg  injected  subcutaneously  (17).  Sera  were  collected  from  all 
vaccinated  subjects  immediately  before  the  first  dose  and  at  2-wk  intervals  thereafter.  In 
addition,  a  serum  sample  was  obtained  from  Dr.  Ofek,  that  had  a  documented  type-24 
streptococcal pharyngitis.  The latter serum was obtained 8 wk after the pharyngitis.  All sera 
were heat inactivated at 56°C for 30 rain before use in the ELISA or opsonic tests (see below). 
ELISA.  The ELISA was performed according to the principles of Engvall and  Perlmann 
(20)  and as described by Russel et al.  (21). The various M  protein antigens were adsorbed  to 
12-  ×  75-mm polystyrene tubes  (Falcon  Labware,  Div. of Becton, Dickinson  & Co., Oxnard, 
Calif.)  at  a  concentration  of 5 #g/ml  in 0.1  M  carbonate  buffer at  pH  9.6.  1 ml of antigen 
solution  was  added  to each  tube,  incubated  for 3  h  at  37°C,  and  stored  at  4°C  until  used. 
Before use, the tubes were washed  three times with 0.15  M  NaC!  (saline)  supplemented  with 
0.15% Tween-20 (saline-Tween). Serial, twofold dilutions of the test serum in 0.02 M phosphate/ 
0.15 M  NaCI, pH 7.4 (PBS) supplemented with 0.05% Tween-20 (PBS-Tween) were added to 
the antigen-coated tubes and incubated at 37°C for 3 h. The tubes were then washed thoroughly 
as above, and  l ml of alkaline phosphatase-conjugated rabbit anti-human IgG (Microbiological 
t Abbreviations used in this paper: CB, cyanogen bromide-derived peptide(s)  of pepsin extract of type-24  M 
protein; CNBr, cyanogen bromide; ELISA, enzyme-linked immunosorbent assay; PBS, 0.02 M phosphate/ 
0.15 M NaCI, pH 7.4; PBS-Tween, PBS supplemented with 0.05% Tween; pep M5, pepsin extract of type- 
5 M protein; pep M6, pepsin  extract of type-6 M protein; pep M24, pepsin  extract of type-24  M protein; 
saline,  0.15  M  NaCI;  saline-Tween, saline  supplemented  with  0.05% Tween-20;  SDS, sodium  dodecyl 
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Associates, Walkersville,  Md.), diluted 1:500 in PBS-Tween, was added and incubated overnight 
at 37°C. After washing the tubes once more with saline-Tween, 1 ml ofp-nitrophenyl phosphate 
(1  mg/ml,  Sigma Chemical Co.,  St.  Louis, Mo.)  in  0.1  M  carbonate buffer  (pH  9.6)  that 
contained 1 mM MgCI2 was added. The reaction was allowed to proceed for 1 h at 37°C and 
was stopped by the addition of 0.1  ml of 1 M  NaOH. Absorbance was read at 400 nmol in a 
Junior Coleman spectrophotometer (Perkin-Elmer Corp., Instrument Div., Norwalk, Conn.). 
The titer of the test serum was recorded as the inverse of the last serum dilution that gave an 
absorbance >0. h 
Inhibition experiments were performed by making serial, 10-fold dilutions of soluble antigen 
in 0.5 ml PBS to which was added 0.5 ml of a constant dilution of human serum. The mixture 
was incubated at 37°C for 30 min and then added to the antigen-coated tubes. The dilution of 
human serum used was one that was known to yield an absorbanee of 0.6-0.8 at 400 nmol in 
the absence of absorbing antigen. 
Opsonophagocytic Assay.  In vitro phagocytosis tests for type-specific opsonic antibody were 
performed as previously described (16).  The assay mixtures consisted of 0.4 ml of fresh blood 
supplemented with 10 U/ml of heparin, 0.05 ml of a standard suspension of streptococci, and 
0.1 ml of test serum. The ratio of streptococcal colony-forming units:leukocyte was ~ 10:1. The 
percentage of neutrophils that ingested streptococci (percent phagocytosis) was estimated by 
microscopic counts of stained smears prepared from the assay mixtures after incubation for 30 
rain. A  positive opsonic antibody response was recorded if in three separate tests the serum 
produced phagocytosis of 20% or greater, whereas phagocytosis of the same organism in the 
presence of nonimmune rabbit serum was <0.5 that of the test serum in each assay. 
Streptolysin  0  and Streptozyme Antibody Assays.  These  assays were  performed  as previously 
described  (22).  The  streptozyme reagent  was  purchased  from  Wampole Laboratories, Div. 
Carter Wallace, Cranbury, N. J. 
Results 
After immunization, all 12 individuals developed greater than fourfold rises in pep 
M24 antibody titers 8 wk after the initial injection, whereas two individuals developed 
fourfold or greater rises in titer against the heterologous pep M6 and pep M5 antigens 
(Fig.  1). None of the vaccinees developed a  rise in antibody titer to streptolysin O  or 
streptozyme  reagent  (data not  shown).  The  two  cross-reactive sera  and  one  of the 
type-specific sera were used in the following studies. 
Inhibition  of Cross-Reactive Sera with Pep M  Proteins.  Both  of the sera that  showed 
rises in cross-reactive antibody titers against pep M5  and pep M6 in the ELISA also 
showed  low levels of opsonic antibodies against type-6, but  not  type-5, streptococci 
(Table I). These results suggested that type-6 M  protein shared a  common antiphag- 
ocytic determinant with pep M24.  To  further investigate this possibility, one of the 
cross-reactive sera  was  preincubated  with  the  homologous  or  heterologous  pep  M 
proteins. The opsonization of type-6 streptococci by the pep M24 immune serum was 
blocked only by pep M6  (Table II). Surprisingly, the antibody was not inhibited by 
the immunizing antigen, pep M24.  Neither pep M5 nor pep M6 inhibited opsoniza- 
tion of the vaccine strain of type-24 streptococci. 
In  contrast  to  the  inhibition of opsonization  tests,  ELISA showed  that  antibody 
against pep M24  was partially inhibited by pep  M5  and  pep  M6,  although  1,000- 
10,000  times  more  of the  heterologous  antigens  was  required  to  achieve  inhibition 
comparable  to  that  of the  homologous  pep  M24.  Antibody  against  pep  M6  was 
inhibited  by  pep  M5  and  pep  M6  but  not  at  all  by  pep  M24  (Fig.  2).  Pep  M24 
partially inhibited  antibody  against  pep  M5,  and  pep  M6  inhibited  100%  of this 
antibody. Interestingly, pep  M6 was  -~ 10  times more effective in blocking antibody 
against pep M5 than the homologous antigen. n- 
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Fxo.  1.  The primary  immune  response to pep M24, pep M6, and  pep M5 after  immunization 
with pep M24 in human volunteers as measured by the ELISA. Bars represent mean titers +  SD. 
TABLE  I 
Assays for Opsonic Antibodies Against Types-24, -6, and -5 Streptococci in Cross-Reactive Sera of Two 
Humans Immunized with Pep M24 
Serum 
ELISA titer against: 
Opsonic antibodies (per- 
cent phagocytosis of strep- 
tococci)* 
pep M24  pep M6  pep M5  type 24  type 6  type 5 
% 
R.F. 
Preimmune  1,024  512  <256.1:  4  8  2 
Immune  32,768  8,192  2,048  72  54  3 
R.P. 
Preimmune  256  512  <256  0  6  0 
Immune  32,768  2,048  2,048  69  62  2 
* Opsonophagocytosis tests were performed as described in Materials and Methods. 
The lowest dilution of serum tested in these assays was 1:256. 
Inhibition of Cross-Reactive Sera with Peptide Fragments of Pep M24.  To investigate the 
possibility that  the cross-reactive antibody that  failed to react with the immunizing 
pep M24 antigen was raised against an inaccessible determinant in the uncleared pep 
M24 protein, we tested the ability of peptide fragments derived by CNBr digestion 
(see below) to inhibit the cross-reactive antibodies against pep M6 (Fig. 3). A mixture 
of the larger CNBr-derived peptides of pep M24  (CB)  fragments, CB 1-2, resulted in 
>50% inhibition of the assay, whereas pep M24 did not block antibody at even higher 
molar concentrations.  Preincubation  with  the  smaller  peptides,  CB3-7,  resulted  in 1030  ANTIGENIC STRUCTURE  OF M  PROTEIN 
TABLE II 
Inhibition of Cross-Reactive and Type-Specific Opsonic Antibodies in a Cross-Reactive Serum of a Pep M24 
Vaccinee * 
Streptococci  Inhibitor  Percent  phagocytosis 
Type 6 
Type 24 
% 
None  52 
Pep M5  48 
Pep M6  6 
Pep M24  62 
None  42 
Pep M5  48 
Pep M6  44 
Pep M24  2 
* Opsonic antibodies against type~6 and type-24 streptococci were assayed in timed phagocytosis tests (see 
Materials and Methods). The opsonic inhibitory activity of each of the pep M proteins was assayed by 
mixing 0.1  ml of diluted serum with  100/~g pep M protein dissolved in 0.1  ml PBS, incubating the 
mixture at 37°C for 30 min, and using the treated serum to preopsonize type-24 or type-6 streptococci as 
previously described (15). 
minimal inhibition, and pep M6, the homologous antigen, was an effective inhibitor 
at very low concentrations. These results suggested that pep M24  possessed a  buried 
determinant that cross-reacted with an exposed determinant(s)  on pep M6. 
Inhibition  of Type-Specific Sera with Pep M24 and Peptide Fragments.  Previous studies 
showed that two of the CNBr fragments of pep M24, CB 1 and CB2, each contained 
~90  amino  acid  residues  and  were  both  found  to  have  NH2-terminal  amino  acid 
sequences identical with the intact pep M24  (12,  18). The remaining five fragments, 
CB3, CB4,  CB5, CB6,  and CB7,  ranged from  ~35  to 40 amino acid residues in size 
and had amino acid sequences different from CB 1 and CB2 but identical with each 
other through the first 20 residues from their NH2-terminal ends. It was of interest to 
compare  the  immunochemical  properties of these  two  classes of peptides  that  had 
totally different repeating sequences by using the highly sensitive ELISA. 
Inhibition experiments were designed to block the binding of antibody to pep M24, 
with  the parent  protein and  mixtures of the CNBr peptides as soluble inhibitors of 
serum from one of the pep NI24 vaccinees that did not show cross-reactions with pep 
M5 or pep M6 and from an individual with a  natural type-24 streptococcal infection 
(Fig. 4). As expected, the intact pep M24  was a  very effective inhibitor of both sera. 
A mixture of the smaller CNBr peptides, CB3-7, was least inhibitory, requiring 50,000 
times the concentration of the parent  protein to reach  50%  inhibition of both sera. 
The inhibition by the larger peptides, CB 1-2, was of particular interest because of the 
differential pattern of inhibition of the two immune sera. The biphasic curve obtained 
by preincubation of the naturally immune serum  with CB1-2  indicated that  ~40% 
inhibition  was  achieved  with  much  lower  conceiatrations of these  soluble peptides 
than that necessary to inhibit the serum of the vaccinee. 
To further define the differential pattern of inhibition of the two immune sera, the 
sera  were  preincubated  with  the  purified  peptides,  CB1  and  CB2  (Fig.  5).  Each 
peptide was  an  effective inhibitor of the serum  of the vaccinee, resulting in similar 
sigmoid curves that approached  100% inhibition. Inhibition of the naturally immune 
serum  with  CB2  showed  a  clearly defined, biphasic curve  with  plateaus at  30  and JAMES  B.  DALE,  ITZHAK OFEK,  AND  EDWIN  H.  BEACHEY  1031 
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Fro. 2.  Inhibition of cross-reactive serum antibodies from an individual immunized with pep M24. 
Increasing concentrations  of pep M24  (O), pep M6 (O), and pep M5  (n) were used to inhibit 
antibody binding to each of the immobilized antigens. The dashed lines represent inhibition by the 
homologous antigen. 
65% inhibition. Preincubation with CB2 achieved 30% inhibition at molar concentra- 
tions below those of the native antigen,  thus suggesting enrichment  of an  antigenic 
determinant.  Preincubation of the naturally immune  serum with  CB1  resulted in a 
monophasic  curve  that  approached  100%  inhibition  at  the  highest  concentration 
tested. High concentrations (up to 50 nmol) of the heterologous pep M6 and pep M5 
were not inhibitory for either serum. 
Discussion 
The validity of the results obtained in the ELISA is dependent upon the purity of 
the antigen used. We believe that the pep M  antigens prepared for these assays satisfy 
the most stringent criteria of homogeneity as judged by electrophoresis in SDS-gels, 
quantitative amino acid analysis, and amino terminal sequencing (12). Our previous 1032  ANTIGENIC  STRUCTURE  OF  M  PROTEIN 
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FIG.  3.  Inhibition of cross-reactive serum antibodies from an individual immunized with pep M24. 
Increasing concentrations of pep M6 (O), pep M24  (O),  CB1-2  (&), and CB3-7  (A)  were used to 
inhibit antibody against pep M6 in the ELISA. 
data indicated that  such preparations  resulted in highly sensitive and  type-specific 
assays by the ELISA (17, 23). 
In  this  study,  immunization  with  pep  M24  antigen  led  to  the  production  of 
antibody  in  two  individuals  that  cross-reacted  with  pep  M5  and  pep  M6  in  the 
ELISA. Both of these also showed a  rise in opsonic antibody against type-6, but not 
against  type-5, streptococci. However, the cross-reactive opsonic antibodies against 
type-6 streptococci could be inhibited by the pep M6 antigen only. By the ELISA, 
pep M5  partially blocked antibodies against  pep M6.  Interestingly, however, these 
antibodies could not be blocked in either assay by the immunizing antigen, pep M24. 
The ability of the CB peptides to inhibit the cross-reactive antibody against pep M6 
as determined by ELISA suggested that  the cross-reactive antibodies were directed 
against a buried antigenic site in the pep M24 molecule, and that the buried site(s) 
must  be  the  same  as  an  exposed  site(s)  on  pep  M5  and  pep  M6.  Similar  buried 
determinants have been reported for other bacterial protein molecules. These include 
fragment A  of diphtheria toxin (24), fragment A  of cholera enterotoxin (25), and a 
portion  of tetanus  toxin  (26).  Nonbacterial  proteins,  including  hemocyanin  (27), 
serum albumin (28-30), immunoglobulin (31,  32) and myelin basic protein (33) also 
have been reported to contain inaccessible antigenic regions that became exposed only 
after fragmentation of the intact  molecules. Only 2  of the  12  vaccinees responded 
immunologically to these apparently buried regions of pep M24, which suggested that 
during antigenic processing the inacessible cross-reactive region(s) of the M  protein 
molecule may occasionally become exposed in vivo. 
In regard to the immunological cross-reactions among the apparently homogeneous 
pep  M  protein  serotypes,  the  covalent  structural  homologies  recently  recognized 
among  pep  M  proteins  may be  of relevance  (34,  35).  Several  of the  amino  acid 
residues were found to be common to pep M5, pep M6, and pep M24, which suggested 
that conservation of certain amino acids may account for the preservation of a specific 
tertiary structure in these three distinct M  protein molecules. Whether or not these 
structures allow presentation of  common antigenic moieties to account for the observed 
cross-reactions, however, remains to be proved. JAMES B.  DALE, ITZHAK OFEK,  AND  EDWIN  H.  BEACHEY 
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FIo. 4.  Inhibition of  antibodies from an individual vaccinated with pep M24 (Q) and an individual 
with naturally  acquired immunity  to type-24 streptococci (O). Increasing concentrations of pep 
M24 (top), CB1-2 (middle), and CB3-7 (bottom) were used to inhibit the binding of antibody to 
pep M24 in the ELISA. 
An alternative  explanation  for the rise in antibody titers against  the heterologous 
types-5 and -6 streptococci during pep M24 immunization is that the two volunteers 
had intercurrent  infections with these serotypes. This possibility seems highly remote, 
however, because (a)  types-5 and -6 streptococcal infections are relatively rare in the 
population under study (36), (b) the immune response occurred within an 8-wk period 
and  the  probability  that  2  of  12  volunteers  contracted  such  infections  would  be 
extremely small,  and  finally  (c)  neither of the subjects developed a  rise in antistrep- 
tolysin O  or streptozyme antibody titers. 
Having recently established  the partial  covalent structure of pep M24 (12,  16,  18), 
we attempted  to pinpoint  the  antigenic  site(s)  of the  molecule responsible  for type- 
specific  immunity:  Amino  acid  sequence  analyses  had  revealed  repeating  identical 
sequences in pep M24 (12,  18). These repeating sequences were found to occur in two 
classes of peptides.  The larger peptides,  CB1  and CB2, were each composed of ~90 
amino  acid residues,  and  each contained  amino acid sequences  identical  with  each 1034  ANTIGENIC STRUCTURE OF M PROTEIN 
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FIG.  5.  Inhibition of serum from an individual vaccinated with pep M24  (O)  and an individual 
with  naturally acquired  immunity to  type-24 streptococci  (O).  Increasing concentrations of pep 
M24 (top), CBL  (middle), and CB2 (bottom) were used to inhibit antibody binding to pep M24 in 
the ELISA. 
other and with the amino terminal region of the intact pep M24 molecule through at 
least  the  first  27  residues.  The remaining five peptide  fragments,  CB3, CB4, CB5, 
CB6,  and  CB7  were  smaller  (35-40  amino  acid  residues)  and  had  amino  acid 
sequences different from CB1  and CB2 but identical with each other for the first  20 
residues  from  their  amino  terminal  ends  (12).  Each  of the  peptide  fragments  was 
shown to share type-specific antigenic determinants (12,  18). 
It  was  of particular  interest  to  determine  if these  peptides  would  inhibit  type- 
specific antibodies from the immune sera of the pep M24 vaccinees. Our data obtained 
from inhibition studies of one of these sera and of a  serum from an individual who 
had experienced a natural infection with type-24 streptococci indicated that pep M24 
possessed more than one distinct type-specific antigenic determinant. The serum from 
the  naturally  infected  individual  contained  one  population  of antibodies  directed 
toward  an  antigen(s)  present  in  CB2  but  not  in  CB1  and  another  population  of JAMES B.  DALE, ITZHAK OFEK, AND EDWIN H.  BEACHEY  1035 
antibodies directed toward an antigen(s) present in both of these peptides. The person 
vaccinated with pep M24 and the person with natural immunity to type-24 strepto- 
cocci both had serum antibodies directed against the smaller peptide fragments, CB3- 
7. 
These results are consistent  with  those of Fischetti  (14)  who described  the devel- 
opment of a family of type-specific antibodies to type-6 M  protein in the immune sera 
of humans after natural streptococcal infections and in the sera of rabbits hyperim- 
munized with type-6 streptococci. By radiocompetitive assays he obtained evidence 
that suggested that opsonic antisera bound to the majority of the antigenic sites on 
the M6 molecule, whereas nonopsonic, cross-reactive antisera raised against heterol- 
ogous serotypes of M  protein reacted with only a  small percentage of the antigenic 
sites recognized by M6 antiserum.  Furthermore,  the cross-reactions among M  types 
were correlated with the presence of common peptide fragments, which suggested a 
certain  degree of structural  similarity  among cross-reactive serotypes of M  protein 
(15).  The question as to whether or not certain of the cross-reactive determinants are 
buried or inaccessible in the intact M  protein molecule, however, was not addressed. 
Our data suggest that certain of the cross-reactive determinants are inacessible in the 
intact molecule and are recognized by the immune system of only a small percentage 
of vaccinees in whom the buried antigenic site may become exposed during processing 
in  vivo.  Certain  of the  buried  antigenic  sites  may prove to  afford cross-protective 
immunity similar to that shown in our study between pep M24 and pep M6. Cross- 
reactions  to  such  shared  determinants  may also  account  for the  limited  degree of 
heterologous protection recently reported by Wittner and Fox  (37)  who immunized 
mice with a  trivalent vaccine that contained acid extracts of types-l, -3, and -12 M 
proteins.  In  addition  to  protection  against  the  vaccine  serotypes,  the  immunized 
animals were also protected against challenge infections with types-6 and -14 strep- 
tococci  (37).  Whether  or  not  a  single  determinant  among the  many distinct  type- 
specific determinants in an M  protein molecule would be sufficient by itself to raise 
protective antibodies  remains unknown.  Recent  studies  in our laboratories,  2 on the 
immunogenicity of purified  peptide  fragments, however, suggest  that  opsonic anti- 
bodies can be raised  against  a  limited  number of the type-specific determinants  in 
any given M  protein molecule. 
In conclusion, our studies indicate that (a) not all type-specific determinants of M 
protein are opsonogenic, perhaps because some are not exposed on the bacterial cell 
surface,  (b)  although  M  protein  opsonogens  are  generally  type specific,  a  few  are 
common to more than one serotype, which indicates that more than one opsonogenic 
determinant  may be exposed on the cell, and  (c) some type-specific antigenic deter- 
minants that  are not opsonogenic for the homologous type may be opsonogenic for 
another M  type, which  suggests that  the cross-reactive opsonogen that  is buried  in 
one type of M  protein may be present and exposed on the surface of another M  type. 
Thus, continued identification of the antigens of various M  proteins may yield a pool 
of small  polypeptides,  all  representing  opsonogens  that  ultimately  can  be  used  to 
induce broad protection against many serotypes with maximal economy of antibody 
production and with relatively small amounts of total protein injected. 
z Beachey, E. H., J. M. Seyer, and A. H. Kang. Primary structure of protective antigens of type 24 
streptococcal M protein. Manuscript submitted for publication. 1036  ANTIGENIC  STRUCTURE OF M  PROTEIN 
Summary 
The  heterogeneity  of  a  pepsin  extract  of  type-24  M  protein  (pep  M24)  was 
demonstrated  by absorption of type-specific and cross-reactive human antisera  with 
M  protein fragments and heterologous serotypes of M  proteins, pepsin extract of type- 
5  M  protein  (pep  M5)  and  pepsin  extract  of type-6  M  protein  (pep  M6).  2  of 12 
individuals  immunized  with  pep  M24  developed  significant  rises  in  antibody titers 
against  pep  M5  and  pep  M6,  as  measured  by  the  enzyme-linked  immunosorbent 
assay. The same individuals also developed opsonic antibodies against type-6, but not 
type-5, streptococci, which suggested the development  of cross-protective immunity. 
Inhibition studies of one of these sera with the heterologous pep M  proteins showed 
that  the  cross-reactive  antibodies  against  pep  M6  could  not  be  blocked  by  high 
concentrations  of pep  M24,  the  immunizing  antigen;  these  antibodies  could  be 
blocked,  however,  by  cyanogen  bromide-derived  peptide  fragments  of pep  M24, 
which suggested  that  the  cross-reactive  antibody was raised  against  an  inaccessible 
site(s)  in the pep M24 molecule. Inhibition studies of type-specific immune sera with 
pep  M24  and  peptides  derived  therefrom  indicated  that  the  M  protein  molecule 
contained  multiple  distinct  as well  as identical  type-specific antigenic  determinants 
that are unequally distributed  among the seven derived peptide  fragments. 
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for secretarial assistance. 
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